ovarian cancer. It is urgent for the clinic to develop in vivo molecular imaging methods to detect HER2 expression in tumor tissues. Radionuclide-based molecular imaging
including positron emission tomography (PET)/computed tomography (CT) and single-photon emission computed tomography (SPECT)/CT
embracing whole body
semi- quantitative
real-time and dynamic inherent advantages
have become the key players in the precise diagnosis and treatment of tumors
therefore
radionuclide-labeled
HER2-targeted molecular image probes and the related applications have been developed extensively. In this paper
the research progress of molecular imaging probes based on radionuclide-labeled HER2 full-sized antibodies and nanobodies as well as their PET/CT and SPECT/CT imaging of HER2 positive tumors were concisely reviewed.